Liability Related to Sale of Future Royalties (Tables)

9 Months Ended

Sep. 30, 2023

The following is a summary of our liability related to sale of future royalties for the nine months ended September 30, 2023 (in thousands):

Proceeds from sale of future royalties	$	500,000
Royalty payments to Royalty Pharma		(27,814	)
Interest expense related to sale of future royalties		50,541
Liability related to sale of future royalties as of September 30, 2023		522,727
Issuance costs related to sale of future royalties		(10,434	)
Amortization of issuance costs related to sale of future royalties as of September 30, 2023		407
Net liability related to sale of future royalties as of September 30, 2023	$	512,700